{"disease":{"id":"remission","name":"remission"},"drugs":{"marketed":[{"drug_id":"aripiprazole","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abilify","generic_name":"aripiprazole","company_name":"Generic (originally Otsuka/BMS)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Third-generation antipsychotic (D2 partial agonist)","quality_score":63,"revenue":"3000","mechanism":"Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it."},{"drug_id":"desonide","indication_name":"Crohn's disease in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verdeso","generic_name":"DESONIDE","company_name":"Padagis Us","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"budesonide","indication_name":"Crohn's disease in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pulmicort Respules","generic_name":"BUDESONIDE","company_name":"AstraZeneca K.K.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"olanzapine","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":"300","mechanism":null},{"drug_id":"lithium-citrate","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Citrate","generic_name":"LITHIUM CITRATE","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium","quality_score":10,"revenue":null,"mechanism":"Lithium Citrate works by inhibiting glycogen synthase kinase-3, a key enzyme involved in the regulation of various cellular processes."},{"drug_id":"quetiapine","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"phenytoin","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenytoin Sodium","generic_name":"PHENYTOIN","company_name":"Viatris","drug_phase":"marketed","molecular_target":"Sodium channel protein type 2 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":70,"revenue":null,"mechanism":"Phenytoin Sodium works by stabilizing the threshold against hyperexcitability caused by excessive stimulation."},{"drug_id":"mesalazine","indication_name":"Ulcerative colitis in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rowasa","generic_name":"Mesalazine","company_name":"Meda Pharms","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Aminosalicylate [EPC]","quality_score":65,"revenue":null,"mechanism":"Rowasa works by blocking the production of prostaglandins, which are chemicals that cause inflammation in the rectum and colon."},{"drug_id":"etrasimod","indication_name":"Induction of remission in adults with moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etrasimod","generic_name":"etrasimod","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":64,"revenue":null,"mechanism":"Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes."},{"drug_id":"etrasimod","indication_name":"Maintenance of clinical response and endoscopic remission in adults with moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etrasimod","generic_name":"etrasimod","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":64,"revenue":null,"mechanism":"Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes."},{"drug_id":"etrasimod","indication_name":"Induction of clinical remission in adults with moderately to severely active Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etrasimod","generic_name":"etrasimod","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":64,"revenue":null,"mechanism":"Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes."},{"drug_id":"etrasimod","indication_name":"Maintenance of clinical response and endoscopic remission in adults with moderately to severely active Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etrasimod","generic_name":"etrasimod","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":64,"revenue":null,"mechanism":"Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes."},{"drug_id":"carbamazepine","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tegretol","generic_name":"carbamazepine","company_name":"Novartis AG (originally Geigy)","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"Mood Stabilizer [EPC]","quality_score":62,"revenue":null,"mechanism":"Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain."},{"drug_id":"lamotrigine","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lamictal","generic_name":"lamotrigine","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha","drug_class":"Anti-epileptic Agent [EPC]","quality_score":55,"revenue":null,"mechanism":null},{"drug_id":"risperidone","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Risperdal","generic_name":"risperidone","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Atypical Antipsychotic [EPC]","quality_score":10,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors for schizophrenia and bipolar disorder."},{"drug_id":"ziprasidone","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Geodon","generic_name":"ziprasidone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aspartate aminotransferase, cytoplasmic, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical antipsychotic (second-generation)","quality_score":10,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors with the least metabolic side effects in its class."},{"drug_id":"mesa","indication_name":"Ulcerative colitis in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MESA","company_name":"Meda Pharms","drug_phase":"marketed","molecular_target":"Arachidonate 5-lipoxygenase, Peroxisome proliferator-activated receptor gamma, Prostaglandin G/H synthase 1","drug_class":"","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"velsipity","indication_name":"Induction of remission in adults with moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velsipity","generic_name":"Etrasimod Arginine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":67,"revenue":null,"mechanism":"Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs."},{"drug_id":"velsipity","indication_name":"Maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velsipity","generic_name":"Etrasimod Arginine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":67,"revenue":null,"mechanism":"Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs."},{"drug_id":"velsipity","indication_name":"Induction of clinical remission in adults with moderately to severely active Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velsipity","generic_name":"Etrasimod Arginine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":67,"revenue":null,"mechanism":"Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs."},{"drug_id":"velsipity","indication_name":"Maintenance of clinical response and remission in adults with moderately to severely active Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velsipity","generic_name":"Etrasimod Arginine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":67,"revenue":null,"mechanism":"Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs."},{"drug_id":"carbamazepin","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carbamazepin","company_name":"Enanta Pharmaceuticals, Inc","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lithium","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithobid","generic_name":"lithium carbonate","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3","drug_class":"Mood stabilizer","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"phenobarbitone","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phenobarbitone","company_name":"Institute of Child Health","drug_phase":"phase_1","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lithium-carbonate","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithium Carbonate","generic_name":"LITHIUM CARBONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glycogen synthase kinase-3","drug_class":"lithium carbonate","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"primidone","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mysoline","generic_name":"PRIMIDONE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 3","drug_class":"Anti-epileptic Agent [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dilantin","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilantin","generic_name":"Phenytoin Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3","drug_class":"phenytoin","quality_score":80,"revenue":null,"mechanism":"Phenytoin exerts its therapeutic effect by voltage-dependent blockade of membrane sodium channels."},{"drug_id":"seroquel","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"risperdal","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Risperdal","company_name":"Ohio State University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"daunorubicin-hydrochloride","indication_name":"Remission induction in pediatric and adult acute lymphocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAUNORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"daunorubicin-hydrochloride","indication_name":"Remission induction in adult acute nonlymphocytic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAUNORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"olsalazine","indication_name":"Maintenance of remission of ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OLSALAZINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":41,"revenue":null,"mechanism":"Olsalazine is converted to 5-ASA by colonic bacteria, which has a topical anti-inflammatory effect on colonic epithelial cells."},{"drug_id":"abilify","indication_name":"Bipolar disorder in remission","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abilify","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"niacin","indication_name":"Remission of prediabetes","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nicotinic Acid","generic_name":"NIACIN","company_name":"MEDPOINTE PHARM HLC","drug_phase":"marketed","molecular_target":"NAD synthase","drug_class":"Vitamin C [EPC]","quality_score":55,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":35,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT05597709","title":"Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China","phase":"","overall_status":"RECRUITING","enrollment_count":2900,"lead_sponsor_name":"Wuxi Hisky Medical Technology Co Ltd","has_results":false},{"nct_id":"NCT05905003","title":"AMP SCZ® Observational Study: PREDICT-DPACC","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2617,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT01005277","title":"Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03586401","title":"Creating a Decision Support System for the Corporate Management of Physical Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT07030686","title":"Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03123640","title":"Improving Drug Safety in Emergency Patients -a Randomized Controlled Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":806,"lead_sponsor_name":"Diakonhjemmet Hospital","has_results":false},{"nct_id":"NCT04769947","title":"Italian Treatment Free Remission Registry","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Turin, Italy","has_results":false},{"nct_id":"NCT00268528","title":"Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission","phase":"","overall_status":"COMPLETED","enrollment_count":720,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT00897507","title":"DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":520,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT01307579","title":"Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":517,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT05194943","title":"Trends and Safety in Revisional Bariatric Surgery in Italy","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"University of Roma La Sapienza","has_results":false},{"nct_id":"NCT04986124","title":"Quality of Life in Chinese Working and School Age Population With MDD","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT07149467","title":"Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":454,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT06149910","title":"Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma","phase":"","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"All4Cure","has_results":false},{"nct_id":"NCT01790152","title":"Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT05057676","title":"Autoimmune Intervention Mastery Course Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Terry L. Wahls","has_results":false},{"nct_id":"NCT05433077","title":"Support and Post-therapeutic Rehabilitation for Women in Complete Remission of Breast Cancer in a Thermal Environment","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Centre Jean Perrin","has_results":false},{"nct_id":"NCT05965232","title":"FIbrosis and Steatosis in Patients With Psychiatric Illness","phase":"","overall_status":"COMPLETED","enrollment_count":385,"lead_sponsor_name":"Centre Hospitalier Esquirol","has_results":false},{"nct_id":"NCT03972982","title":"Effects of Structured Simplified Short-term Intensive Insulin Therapy on Long-term Glycemic Remission","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":330,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04321863","title":"Stratifying Crohn's Using Biomarker Assessment","phase":"","overall_status":"UNKNOWN","enrollment_count":315,"lead_sponsor_name":"NHS Greater Glasgow and Clyde","has_results":false},{"nct_id":"NCT05224661","title":"Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":303,"lead_sponsor_name":"Center for International Blood and Marrow Transplant Research","has_results":false},{"nct_id":"NCT03197974","title":"RCT of a Web-based Intervention to Improve Quality of Life in Late Stage Bipolar Disorder (ORBIT)","phase":"NA","overall_status":"COMPLETED","enrollment_count":302,"lead_sponsor_name":"Swinburne University of Technology","has_results":false},{"nct_id":"NCT05917405","title":"Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":302,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT06426758","title":"Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Xiao-Ming Mao","has_results":false},{"nct_id":"NCT05447572","title":"FIT Combining FC for Predicting MH and Histology Remission in UC","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Shandong University","has_results":false},{"nct_id":"NCT06553612","title":"Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients at the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":268,"lead_sponsor_name":"Centre Francois Baclesse","has_results":false},{"nct_id":"NCT04743102","title":"Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Beijing Chao Yang Hospital","has_results":false},{"nct_id":"NCT04921033","title":"Exclusive Enteral Nutrition in Patients With Ileocaecal Crohn's Disease","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":256,"lead_sponsor_name":"Duzce University","has_results":false},{"nct_id":"NCT03226301","title":"A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":230,"lead_sponsor_name":"Stichting Hemato-Oncologie voor Volwassenen Nederland","has_results":false},{"nct_id":"NCT05111665","title":"Decentering and Relapse/Recurrence in MBCT for Depression in Adults","phase":"NA","overall_status":"COMPLETED","enrollment_count":227,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT03887156","title":"Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":227,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05166798","title":"Optimal Dose of a Cognitive Control Training for Depression Vulnerability","phase":"NA","overall_status":"COMPLETED","enrollment_count":216,"lead_sponsor_name":"University Ghent","has_results":false},{"nct_id":"NCT03117816","title":"ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":214,"lead_sponsor_name":"Philipps University Marburg","has_results":false},{"nct_id":"NCT06186999","title":"Social and Demographic Determinants of Fatigue in Patients With Inflammatory Bowel Disease in Remission","phase":"","overall_status":"COMPLETED","enrollment_count":208,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false},{"nct_id":"NCT05440747","title":"Treatment Free Remission (TFR) in CML Patients （CML-CP）Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":203,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT06761274","title":"Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03919240","title":"CAR-T Cell Therapy Targeting to CD19 for R/R ALL","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":196,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04333342","title":"Heart Rate Monitoring by Wearable Devices in Graves' Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"Seoul National University Bundang Hospital","has_results":false},{"nct_id":"NCT03574948","title":"5-HTP in Patients With IBD in Clinical and Biologic Remission:Effect on Fatigue Scores","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"University Hospital, Ghent","has_results":false},{"nct_id":"NCT00536601","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT05477589","title":"Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT04232241","title":"Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":167,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT06402422","title":"Vulnerability Markers for Depression","phase":"","overall_status":"COMPLETED","enrollment_count":166,"lead_sponsor_name":"The Hong Kong Polytechnic University","has_results":false},{"nct_id":"NCT01690520","title":"Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":163,"lead_sponsor_name":"Nohla Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03248180","title":"Guided Dose Reduction of Antipsychotic in Patients With Psychosis in Remitted States","phase":"","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03232112","title":"Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"Anders Fink-Jensen, MD, DMSci","has_results":false},{"nct_id":"NCT05073848","title":"Relationships Between Physical Activity and Different Measures of Fatigue in Cancer Survivors","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT04325529","title":"Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Study 1.2 (Stress Manipulation)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":148,"lead_sponsor_name":"Mclean Hospital","has_results":false},{"nct_id":"NCT00093470","title":"Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05557760","title":"Effects of Booster Sessions on Depression Vulnerability Following Cognitive Control Training","phase":"NA","overall_status":"UNKNOWN","enrollment_count":138,"lead_sponsor_name":"University Ghent","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}